Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR).
Subscribe to our email newsletter
The collaboration will focus on conducting Phase 3 clinical trial of Pfizer’s investigational pan-human epidermal growth factor receptor (pan-HER) inhibitor, dacomitinib (PF-00299804), which will be conducted across multiple sites in Asia and Europe.
SFJ president and CEO Robert DeBenedetto said, "With this important, multi-national trial, we are pleased to continue our collaborative relationship with Pfizer and support the clinical development of a promising new agent for the treatment of lung cancer."
Pursuant to the agreement, the funding and clinical development supervision required to produce the data that support a registration dossier on dacomitinib for marketing authorization by regulatory authorities will be provided by SFJ.
Once approved, SFJ is eligible to gain milestone payments and earn-out payments.
Pfizer Oncology president and general manager Garry Nicholson said non-small cell lung cancer remains a difficult disease to treat despite recent advances, and Pfizer is evaluating dacomitinib in NSCLC across lines of therapy and a range of histologies and molecular subtypes.
"By collaborating with SFJ on the continued clinical development of dacomitinib in this patient population, we hope to more immediately bring a new first-line therapy to patients in need," Nicholson added.